Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Prospective,Multicenter,Randomized Controlled Clinical Study of the Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）

NCT02076477 is registered in ClinicalTrials.gov with Sichuan Cancer Hospital and Research Institute as lead sponsor.

NCT NCT02076477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02076477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Prospective,Multicenter,Randomized Controlled Clinical Study of the Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）
Lead sponsor
Sichuan Cancer Hospital and Research Institute
Phase
Phase 3
Overall status
Unknown status
Start date
January 31, 2014
Completion date
October 31, 2020
Enrollment
420 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oligo-metastatic stage iv non-small cell lung cancer